article Open AccessTop 1% cited
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>
Journal of Clinical Oncology · 2009 · Vol. 27(26) · pp. 4247–4253
Alice T. Shaw✉Beow Y. Yeap(Massachusetts General Hospital)Mari Mino–Kenudson(Massachusetts General Hospital)Subba R. Digumarthy(Massachusetts General Hospital)Daniel B. Costa(Massachusetts General Hospital)Rebecca S. Heist(Massachusetts General Hospital)Benjamin Solomon(Massachusetts General Hospital)Hannah Stubbs(Massachusetts General Hospital)Sonal Admane(Massachusetts General Hospital)Ultan McDermott(Massachusetts General Hospital)Jeffrey Settleman(Massachusetts General Hospital)Susumu Kobayashi(Massachusetts General Hospital)Eugene J. Mark(Massachusetts General Hospital)Scott J. Rodig(Massachusetts General Hospital)Lucian R. Chirieac(Massachusetts General Hospital)Eunice L. Kwak(Massachusetts General Hospital)Thomas J. Lynch(Massachusetts General Hospital)A. John Iafrate(Mass General Brigham)
Abstract
EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics. Patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.
Lung Cancer Treatments and MutationsLung Cancer Research StudiesNeuroendocrine Tumor Research AdvancesMedicineKRASLung cancerInternal medicineCrizotinibOncologyAdenocarcinomaAnaplastic lymphoma kinaseCohortCancer
MeSH terms
Erlotinib HydrochlorideGefitinibAnaplastic Lymphoma KinaseAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleGenotypeHumansImmunohistochemistryLung NeoplasmsMale
Funding
- American Association for Cancer Research
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Massachusetts General Hospital
- American Society of Clinical Oncology
- National Institutes of Health
- Genentech
- EMD Serono
- Takeda Oncology
Citations
1,873
FWCI
100.13
field-weighted impact
References
29
Percentile
100%
vs. same field & year
Citations per year
Cited by
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Science Translational Medicine · 2012 · 1,320 citations
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
Frontiers in Oncology · 2017 · 485 citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 2,632 citations
The biology and treatment of EML4-ALK non-small cell lung cancer
European Journal of Cancer · 2010 · 556 citations
Cell death-based treatment of lung adenocarcinoma
Cell Death and Disease · 2018 · 781 citations
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2012 · 928 citations
References
Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000
BMC Cancer · 2002 · 476 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
PLoS Medicine · 2005 · 1,521 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
JNCI Journal of the National Cancer Institute · 2005 · 2,385 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Clinical Cancer Research · 2008 · 975 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.